1 Temu Ilmiah Nasional 2020 Potensi Ekstrak Curcuma Xanthorrhiza Sebagai Terapi Pendamping Tuberkulosis Hamzah Haryo Prakoso 1 , Andre Setiawan 1 , Daffa Sadewa 1 1 Program Studi Kedokteran, Fakultas Kedokteran, Universitas Sebelas Maret, Surakarta Abstract Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis. Most of it attacks the lungs and is still a world health problem. Therapy with a combination of drugs called Anti-Tuberculosis Drugs (OAT) has become a standard and effective cure for TB sufferers as long as it is regular and complete. However, the drawback of OAT is that it has several side effects that allow temporary drug interruption and worsening of clinical manifestations. For that we need companion therapy to overcome this. The purpose of this paper is to search and analyze literature regarding the potential of Curcuma xanthorrhizol extract as a companion therapy for tuberculosis. The method used is by searching the pubmed and google scholar databases with the keywords curcuma xanthorrhiza, curcumin, xanthorrhizol, flavonoids, Mycobacterium tuberculosis, anti-inflammatory, anti-oxidant, gastroprotective and anti-bacterial. Then the literature is selected based on inclusion and exclusion criteria. The results and discussion obtained were that curcuma xanthorrhiza has various active compounds that are useful for preventing side effects of OAT such as curcumin, xanthorrhizol, and flavonoids. Curcuma xanthorrhiza can be used as anti-inflammatory, anti- oxidant, gastroprotective so that side effects such as skin rashes, nausea, vomiting, abdominal pain and others can be prevented. Besides that, curcumin content in Curcuma xanthorrhiza has anti-tuberculosis activity. The conclusion is that curcuma xanthorrhiza extract can be considered as a companion drug for TB patients. It can be done further research on the potential of ginger extract to shorten the duration of TB treatment considering its benefits as anti-tuberculosis. Keywords: tuberculosis, curcuma xanthorrhiza, herb, anti-inflammatory, hepatoprotektif, anti- tuberculosis Pendahuluan Tuberkulosis (TB) masih merupakan salah satu masalah kesehatan masyarakat di dunia. Sebanyak 10 juta insiden TB dilaporkan pada tahun 2018, dengan rata-rata 130 kasus per 100.000 penduduk. Sebagian besar estimasi insiden terjadi di kawasan Asia Tenggara (44%) dimana Indonesia menyumbangkan angka tertinggi yaitu 8%. Secara global 87% kasus TB terkonsentrasi di 30 negara dengan beban TB tinggi. Salah satunya Indonesia yang menempati peringkat 3 kasus terbanyak setelah India dan China. Negara dengan beban tinggi menurut World Health Organization (WHO) didefinisikan berdasarkan 3 indikator yaitu TB, TB/HIV dan MDR-TBC. Terdapat 13 negara yang masuk ke dalam 3 indikator tersebut termasuk Indonesia. 1 Kementerian Kesehatan Republik Indonesia (Kemenkes RI) menyebutkan sebanyak 420.994 kasus terjadi pada tahun 2017, dengan prevelensi sebesar 254 kasus per 100.000 penduduk. Sementara target prevelensi TB di Indonesia adalah 245 kasus per 100.000 penduduk. 2 Dalam merespon urgensinya penanggulangan TB, Indonesia melalui Rencana Pembangunan Jangka Menengah Nasional (RPJMN) telah menargetkan prevelensi TB pada 2024 mendatang berkurang menjadi 190 kasus per 100.000 penduduk. 3 Sedangkan target program